Considering that, in this tumor, Notch3 overexpression correlated with OS and that Notch3 silencing could counteract cisplatin resistance, Notch3 inhibition with SAHA could be applied as a potential therapeutic strategy [322]. This evidence concerns the gene NOTCH3 and neoplasm.